Amgen (AMGN) Cost of Revenue (2009 - 2026)

Amgen has reported Cost of Revenue for 18 years, with the latest figure at $2.7 billion in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue fell 7.55% year-over-year to $2.7 billion; the trailing twelve-month figure through Mar 2026 stood at -$1.8 billion (down 119.67% YoY), and the FY2025 full-year result was $1.3 billion, down 89.8% from the prior year.
• Cost of Revenue for Q1 2026 stood at $2.7 billion, up from -$7.7 billion in the prior quarter.
• The five-year high for Cost of Revenue was $3.2 billion in Q2 2024, with the low at -$7.7 billion in Q4 2025.
• Average Cost of Revenue over 5 years is $1.3 billion, with a median of $1.7 billion recorded in 2022.
• Peak annual rise in Cost of Revenue reached 4240.85% in 2025, while the deepest fall reached 349.0% in 2025.
• Tracing AMGN's Cost of Revenue over 5 years: stood at $1.7 billion in 2022, then surged by 78.13% to $3.1 billion in 2023, then changed by 0.0% to $3.1 billion in 2024, then plunged by 349.0% to -$7.7 billion in 2025, then surged by 135.41% to $2.7 billion in 2026.
• The last three Cost of Revenue figures came in at $2.7 billion (Q1 2026), -$7.7 billion (Q4 2025), and $3.1 billion (Q3 2025), per Business Quant data.

Peer Comparison